| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $3,992 | 1 | 100 |
| Lieber Jonathan I | Chief Financial Officer | 0 | $0 | 1 | $3,992 | $-3,992 |
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Over the last 12 months, insiders at Rallybio Corporation have bought $0 and sold $3,992 worth of Rallybio Corporation stock.
On average, over the past 5 years, insiders at Rallybio Corporation have bought $19.67M and sold $3.5M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $26,050 was made by Lieber Jonathan I () on 2023‑03‑14.
| 2026-02-23 | Sale | Lieber Jonathan I | Chief Financial Officer | 789 0.0137% | $5.06 | $3,992 | +79.64% | |
| 2023-03-14 | Lieber Jonathan I | 5,000 0.0123% | $5.21 | $26,050 | -13.59% | |||
| 2023-03-07 | Sale | PARMAR KUSH | director | 100,000 0.242% | $8.20 | $820,000 | -44.36% | |
| 2023-03-07 | Sale | 5AM Partners V, LLC | 10 percent owner | 100,000 0.242% | $8.20 | $820,000 | -44.36% | |
| 2022-06-03 | Sale | ROCKLAGE SCOTT M | 99,671 0.4398% | $12.50 | $1.25M | -23.70% | ||
| 2022-06-03 | Sale | PARMAR KUSH | 99,671 0.4398% | $12.50 | $1.25M | -23.70% | ||
| 2022-05-23 | Sale | ROCKLAGE SCOTT M | 33,553 0.1126% | $13.00 | $436,189 | -43.36% | ||
| 2022-05-23 | Sale | PARMAR KUSH | 33,553 0.1126% | $13.00 | $436,189 | -43.36% | ||
| 2022-03-21 | Fryer Jeffrey M | See Remarks | 3,000 0.0103% | $8.04 | $24,120 | +4.79% | ||
| 2022-02-08 | Sale | PARMAR KUSH | director | 210,000 0.6366% | $13.05 | $2.74M | -36.62% | |
| 2022-02-08 | Sale | 5AM Opportunities I, L.P. | 10 percent owner | 210,000 0.6366% | $13.05 | $2.74M | -36.62% | |
| 2022-01-19 | Fryer Jeffrey M | See Remarks | 1,400 0.0046% | $8.70 | $12,180 | +7.49% | ||
| 2022-01-13 | Uden Stephen | See Remarks | 5,000 0.0172% | $9.15 | $45,752 | +6.63% | ||
| 2022-01-12 | Uden Stephen | See Remarks | 5,000 0.0176% | $10.55 | $52,750 | -5.66% | ||
| 2022-01-11 | MACKAY MARTIN | Chief Executive Officer | 4,496 0.0146% | $10.65 | $47,882 | -13.16% | ||
| 2022-01-10 | MACKAY MARTIN | Chief Executive Officer | 5,504 0.0172% | $10.10 | $55,590 | -11.65% | ||
| 2022-01-07 | Fryer Jeffrey M | See Remarks | 10,000 0.0313% | $9.41 | $94,069 | -4.69% | ||
| 2021-08-02 | SHANNON TIMOTHY M | director | 76,923 0.2018% | $13.00 | $999,999 | -39.61% | ||
| 2021-08-02 | HUNT RONALD | director | 307,692 0.8073% | $13.00 | $4M | -39.61% | ||
| 2021-08-02 | Hopfner Robert Lorne | director | 576,923 1.5136% | $13.00 | $7.5M | -39.61% |
| Lieber Jonathan I | Chief Financial Officer | 4115 0.0778% | $38,228.35 | 1 | 1 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 4194777 79.3012% | $38.97M | 1 | 0 | <0.0001% |
| ROCKLAGE SCOTT M | 2478969 46.8643% | $23.03M | 0 | 2 | ||
| SHANNON TIMOTHY M | director | 2409712 45.555% | $22.39M | 1 | 0 | <0.0001% |
| PARMAR KUSH | director | 2378969 44.9738% | $22.1M | 1 | 4 | <0.0001% |
| 5AM Partners V, LLC | 10 percent owner | 2378969 44.9738% | $22.1M | 0 | 1 | |
| HUNT RONALD | director | 2301603 43.5112% | $21.38M | 1 | 0 | <0.0001% |
| Hopfner Robert Lorne | director | 2267411 42.8648% | $21.06M | 1 | 0 | <0.0001% |
| 5AM Opportunities I, L.P. | 10 percent owner | 1335637 25.2499% | $12.41M | 1 | 1 | <0.0001% |
| Uden Stephen | See Remarks | 719127 13.5949% | $6.68M | 2 | 0 | +0.48% |
| MACKAY MARTIN | Chief Executive Officer | 282609 5.3427% | $2.63M | 2 | 0 | <0.0001% |
| Fryer Jeffrey M | See Remarks | 47048 0.8894% | $437,075.92 | 3 | 0 | +2.53% |
$5,354,267 | 110 | -35.34% | $57.05M | |
$1,695,621 | 55 | 17.90% | $57.76M | |
$693,326 | 47 | -16.18% | $48.18M | |
$24,478,755 | 37 | -34.59% | $59.55M | |
$95,303,339 | 30 | -13.78% | $54.82M | |
$27,151,286 | 27 | -16.85% | $60.32M | |
$226,127 | 22 | -27.62% | $42.74M | |
$7,733,516 | 17 | 73.42% | $42.32M | |
$17,594,514 | 16 | -20.37% | $42.81M | |
Rallybio Corporation (RLYB) | $39,336,371 | 14 | -17.87% | $49.14M |
$19,300,035 | 11 | 45.88% | $50.53M | |
$45,000,000 | 6 | -31.22% | $55.68M | |
$26,254,149 | 5 | 49.97% | $47.51M | |
$5,306,958 | 5 | 11.70% | $45.69M | |
$657,791 | 4 | -52.05% | $55.68M | |
$97,699 | 4 | -19.04% | $42.8M | |
$67,369,250 | 3 | -22.09% | $53.64M | |
$4,030 | 1 | 9.14% | $46.26M | |
$30,190 | 1 | -42.39% | $45.52M |
| Increased Positions | 13 | +25.49% | 702,051 | +19.34% |
| Decreased Positions | 14 | -27.45% | 134,609 | -3.71% |
| New Positions | 4 | New | 8,395 | New |
| Sold Out Positions | 3 | Sold Out | 94,109 | Sold Out |
| Total Postitions | 50 | -1.96% | 4M | +15.63% |
| Viking Global Investors Lp | $2,966.00 | 9.99% | 4.19M | 0 | 0% | 2025-09-30 |
| Johnson & Johnson | $2,571.00 | 8.66% | 3.64M | 0 | 0% | 2025-09-30 |
| 5Am Venture Management, Llc | $2,567.00 | 8.65% | 3.63M | 0 | 0% | 2025-09-30 |
| New Leaf Venture Partners, L.L.C. | $2,334.00 | 7.86% | 3.3M | 0 | 0% | 2025-09-30 |
| Tpg Gp A, Llc | $2,141.00 | 7.21% | 3.03M | 0 | 0% | 2025-09-30 |
| Pivotal Bioventure Partners Investment Advisor Llc | $1,700.00 | 5.73% | 2.4M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $1,198.00 | 4.03% | 1.69M | -175,888 | -9.4% | 2025-09-30 |
| Almitas Capital Llc | $1,088.00 | 3.66% | 1.54M | -278,765 | -15.34% | 2025-09-30 |
| Vanguard Group Inc | $707.00 | 2.38% | 999,627 | +89,686 | +9.86% | 2025-09-30 |
| Aju Ib Investment Co., Ltd. | $534.00 | 1.8% | 754,678 | 0 | 0% | 2025-09-30 |